Up-Down Oxytocin Infusion

Overview

This study is designed to determine the minimum effective dose (ED90) of infusions of oxytocin for the prevention of uterine atony / postpartum hemorrhage and the need for additional uterotonics, in low risk parturients presenting for an elective CD. The primary outcome measure is the response of effective uterine contraction as either satisfactory or unsatisfactory as determined by the obstetrician blinded to the oxytocin infusion dose. Secondary outcomes will include need for additional uterotonics, calculated intra-operative blood loss and presence of oxytocin related adverse effects.

Full Title of Study: “Up-down Determination of the ED90 of Oxytocin Infusions for the Prevention of Postpartum Uterine Atony in Parturients Undergoing Cesarean Delivery”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Participant, Care Provider)
  • Study Primary Completion Date: August 2008

Interventions

  • Drug: Oxytocin infusion
    • Up-down dosing determination

Arms, Groups and Cohorts

  • Experimental: A

Clinical Trial Outcome Measures

Primary Measures

  • The primary outcome measure is the response of effective uterine contraction as either satisfactory or unsatisfactory as determined by the obstetrician blinded to the oxytocin infusion dose.
    • Time Frame: 3 minutes

Secondary Measures

  • Secondary outcomes will include need for additional uterotonics, calculated intra-operative blood loss and presence of oxytocin related adverse effects.
    • Time Frame: 2 days

Participating in This Clinical Trial

Inclusion Criteria

1. Non-emergent cesarean delivery with planned spinal anesthesia (i.e. elective planned cesarean delivery for malposition, patient choice, cervical pelvic disproportion, previous cesarean delivery and other diagnosis that require a predetermined cesarean delivery) 2. American Society of Anesthesia physical status class I & II (ASA I – Healthy, ASA II - mild and controlled systemic disease, eg. controlled essential hypertension) 3. Age ≥ 18 years 4. Term gestational age (≥ 37 weeks) 5. English-speaking Exclusion Criteria:

1. Morbid Obesity (Body Mass Index ≥ 45 kg/m2) (Morbidly obese parturients require a dose of local anesthetic less than the standardized dose in this study and the blood pressure cuff occasionally needs to be replaced by an intraarterial catheter due to limitations in size) 2. Laboring women 3. Urgent or emergency cesarean delivery 4. Severe hypertensive disease of pregnancy defined as systolic blood pressure (SBP) > 160mmHg, diastolic blood pressure (DBP) > 110mmHg and/or requiring antihypertensive treatment or associated with significant proteinuria 5. Severe maternal cardiac disease 6. Subjects predisposed to uterine atony and postpartum hemorrhage (i.e. placenta previa, multiple gestation, macrosomia, polyhydramnios, uterine abnormalities, or bleeding diathesis, > 2 previous CD) 7. Fetal anomalies /Intrauterine Fetal Demise 8. Failed spinal anesthesia 9. Patient enrollment in another study involving a study medication within 30 days of CD 10. Any other physical or psychiatric condition which may impair their ability to cooperate with study data collection

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • IWK Health Centre
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ronald George, Primary Investigator, MD, FRCPC, Assistant Professor – IWK Health Centre
  • Overall Official(s)
    • Ronald B George, MD FRCPC, Principal Investigator, IWK

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.